Journal of Psychopharmacology
November 1, 2024
Yi-Chun Chang, Renee E Magnan, Michael J Cleveland et al.
2 citations
Limited research considers the quantity and potency of cannabis products along with social context on the subjective effects of real-world cannabis use. This study examined the subjective effects of acute use as a function of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) doses and social context during cannabis use episodes. Ninety-six participants (43.75% male, Mage = 35.73) reporting...
Clinical Pharmacology & Therapeutics
November 1, 2024
Andriy A Gorbenko, Jules A A C Heuberger, Linda E. Klumpers et al.
17 citations
Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the tolerability of cannabis as an analgesic. A...
Cannabis and Cannabinoid Research
October 1, 2024
Carlton Cb Bone, Charles Klein, Kaelas Munger et al.
6 citations
Introduction: In the wake of continued consumer demand despite increasing regulatory scrutiny, there is a need to develop systematic methods for identifying the harm profile of new psychoactive substances derived from hemp. Tetrahydrocannabinol-O (THC-O)-acetate, colloquially known as THCO, is the acetate ester of the principal psychoactive compound in cannabis. The heating of THCO can create...
Psychopharmacology
October 1, 2024
Ardavan Mohammad Aghaei, Lia Urban Spillane, Brian Pittman et al.
9 citations
Recent reports have shown increased cannabis use among women, leading to growing concerns about cannabis use disorder (CUD). While there is preclinical evidence suggesting biological sex influences cannabinoid effects, human research remains scant. We investigated sex differences in the acute response to oral tetrahydrocannabinol (THC) in humans. 56 healthy men and women with prior exposure to...
bioRxiv (Cold Spring Harbor Laboratory)
September 29, 2024
Sabrina Zequeira, Emely A. Gazarov, Alara A. Güvenli et al.
preprint
With increased legalization of recreational and medical cannabis, use of this drug is growing rapidly among older adults. As cannabis use can impair cognition in young adults, it is critically important to understand how consumption interacts with the cognitive profile of aged individuals, who are already at increased risk of decline. The current study was designed to determine how cannabis...
BMC Psychiatry
September 27, 2024
Onrumpha Chuenchom, Thanarat Suansanae, Lumsum Lukanapichonchut et al.
Abstract Background Current treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner. Methods A retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment...
Alcoholism & Drug Abuse Weekly
September 16, 2024
Alison Knopf
The typical conundrum with cannabis use by adolescents and first episode psychosis — which came first? — was displaced by Steven Batki, M.D. in a plenary session at the Cape Cod Symposium on Addictive Disorders (CCSAD) last week. Bakti, who is professor of psychiatry at the University of California San Francisco Weill Institute for Neurosciences, presented his conclusions allowing the audience...
Biomolecules
September 10, 2024
Valeria Lallai, TuKiet T Lam, Rolando Garcia-Milian et al.
Given the increasing use of cannabis in the US, there is an urgent need to better understand the drug's effects on central signaling mechanisms. Extracellular vesicles (EVs) have been identified as intercellular signaling mediators that contain a variety of cargo, including proteins. Here, we examined whether the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), alters EV...
L'Encephale
September 1, 2024
Zélie Billion, M. Hein
INTRODUCTION Cannabis is the most consumed illicit substance in Europe. Although its sale and use remain generally prohibited, European public policies have evolved in recent years by legalizing cannabis for medical use and considering its legalization for recreational use. However, in the literature there are arguments in favor of a particular relationship between cannabis consumption and the...
Psychiatry Research
September 1, 2024
Giuseppe D'Andrea, Clairélaine Ouellet-Plamondon, Marie Villeneuve et al.
Cannabis use is associated with increased psychosis incidence alongside worse outcomes. The role of cannabis may be complex, vary across patients and over time. Yet, few have examined the longer-term trajectories of cannabis use, symptoms and functioning and their inter-relationships. We conducted a 5-year longitudinal study to estimate joint-trajectories of clinical severity, social...